Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789143 | 1.00 | HRH4 (0.45) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL19350614 | 1.00 | HRH4 (0.45) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL754871 | 1.00 | HRH4 (0.45) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL841330 | 1.00 | HRH4 (0.45) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL2600364 | 0.96 | HRH4 (0.43) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL479263 | 0.89 | HRH4 (0.39) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL23841891 | 0.88 | EPHX1 (0.50) | HRH4HRH3GRIA1ADRB2EPHX1 | |
| SCHEMBL1026323 | 0.88 | EPHX1 (0.50) | HRH4HRH3EPHX1KDM4EALDH1A1 | |
| SCHEMBL23696489 | 0.88 | EPHX1 (0.50) | HRH4HRH3EPHX1KDM4EALDH1A1 | |
| SCHEMBL22458762 | 0.88 | EPHX1 (0.50) | HRH4HRH3GRIA1ADRB2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928786-B1 | PROCESSES FOR PREPARING MTT ZEOLITES USING NITROGEN-CONTAINING ORGANIC COMPOUNDS | CHEVRON USA INC (US) | 2016-12-28 | — | — | EP | claimed |
| EP-1928786-A1 | PROCESSES FOR PREPARING MTT ZEOLITES USING NITROGEN-CONTAINING ORGANIC COMPOUNDS | Chevron U.S.A., Inc. (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007027437-A1 | PROCESSES FOR PREPARING MTT ZEOLITES USING NITROGEN-CONTAINING ORGANIC COMPOUNDS | CHEVRON U.S.A. INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TIBA BIOTECH LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20200055883-A1 | CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190345192-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
| US-20190169084-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2019-06-06 | — | — | US | disclosed |
| WO-2010074722-A1 | HIGH ACTIVITY MTT FRAMEWORK TYPE MOLECULAR SIEVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100147741-A1 | High activity MTT framework type molecular sieves | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2010-06-17 | — | — | US | disclosed |
| EP-1928786-A1 | PROCESSES FOR PREPARING MTT ZEOLITES USING NITROGEN-CONTAINING ORGANIC COMPOUNDS | Chevron U.S.A., Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070128106-A1 | BORON-CONTAINING MOLECULAR SIEVE MTT | CHEVRON U.S.A. INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070128106-A1 | BORON-CONTAINING MOLECULAR SIEVE MTT | CHEVRON U.S.A. INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007027437-A1 | PROCESSES FOR PREPARING MTT ZEOLITES USING NITROGEN-CONTAINING ORGANIC COMPOUNDS | CHEVRON U.S.A. INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027437-A1 | PROCESSES FOR PREPARING MTT ZEOLITES USING NITROGEN-CONTAINING ORGANIC COMPOUNDS | CHEVRON U.S.A. INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-7157075-B1 | Process for preparing MTT zeolites using nitrogen-containing organic compounds | CHEVRON U.S.A. INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157075-B1 | Process for preparing MTT zeolites using nitrogen-containing organic compounds | CHEVRON U.S.A. INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | SNRPE, DDX21, DCLRE1B | HRH4 4752/4885HRH3 4695/4885GRIA1 984/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | HRH4 4261/4885HRH3 4228/4885GRIA1 4186/4885 |
| US-20190345192-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | TP53, MYC, CDC73 | HRH4 3999/4885HRH3 3893/4885GRIA1 3897/4885 |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | POLN, TLR9, TSG101 | HRH4 4187/4885HRH3 3364/4885GRIA1 1258/4885 |
| US-20190169084-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | HRH4 2009/4885HRH3 2428/4885GRIA1 782/4885 |
| US-20200055883-A1 | CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER | NME4, NME2, DPYD | HRH4 3249/4885HRH3 3513/4885GRIA1 3622/4885 |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TLR9, TLR3, TSG101 | HRH4 4717/4885HRH3 4165/4885GRIA1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.